Dolutegravir (Tivicay®)

Assessment Status Rapid Review Complete
Drug Dolutegravir
Brand Tivicay®
Indication In combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age.
Assessment Process
Rapid review commissioned 10/02/2014
Rapid review completed 13/03/2014
Rapid review outcome Full Pharmacoeconomic Evaluation Not Recommended